GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » COGS-to-Revenue

Embecta (Embecta) COGS-to-Revenue : 0.35 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta COGS-to-Revenue?

Embecta's Cost of Goods Sold for the three months ended in Mar. 2024 was $102 Mil. Its Revenue for the three months ended in Mar. 2024 was $287 Mil.

Embecta's COGS to Revenue for the three months ended in Mar. 2024 was 0.35.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Embecta's Gross Margin % for the three months ended in Mar. 2024 was 64.55%.

Embecta COGS-to-Revenue Historical Data

The historical data trend for Embecta's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta COGS-to-Revenue Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
COGS-to-Revenue
0.29 0.30 0.31 0.31 0.33

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.34 0.36 0.33 0.35

Embecta COGS-to-Revenue Calculation

Embecta's COGS to Revenue for the fiscal year that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=370.9 / 1120.8
=0.33

Embecta's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=101.8 / 287.2
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embecta  (NAS:EMBC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Embecta's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 101.8 / 287.2
=64.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Embecta COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Embecta's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Embecta (Embecta) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » COGS-to-Revenue
Comparable Companies
LMAT ATRI BLFS OSUR ANIK UTMD WRBY ANGO PLSE SMTI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC WST OCSE:COLO B RMD TSE:4543 XSWX:STMN
Traded in Other Exchanges
JX7:Germany
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Website
https://www.embecta.com
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015